Antibody Information

General Information of This Antibody

Antibody ID	ANI0OAONZ
Antibody Name	Anti-CD46 fully human antibody
Synonyms	Anti-CD46 fully human antibody (ab) Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1
Antigen Name	Membrane cofactor protein (CD46)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

FOR-46 [Phase 1/2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Partial Response (PR)	22.20%
Patients Enrolled	Metastatic castration-resistant prostate cancer (CRPC).
Administration Dosage	Intravenous FOR46 on day 1 of every 21-day cycle. Dose levels ranged from 0.10 mg/kg. the starting dose level, to 3.00 mg/kg. The trial established 2.70 mg/kg to be the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of the agent.
*Related Clinical Trial*
NCT Number	NCT03575819	Clinical Status	Phase 1
Clinical Description	A phase 1 study of FOR46 administered every 21 days in patients with metastatic castration-resistant prostate cancer (mCRPC).
Primary Endpoint	MtD and phase 1b dose=2.70 mg/kg.
Other Endpoint	18 pts had measurable lesions; 8 of 18 (44.44%) had tumor regression, with 4 (22.22%) confirmed partial responses (PR). The median duration of response is > 14 wks (range 9 -31+ weeks).
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT05011188	Clinical Status	Phase 1/2
Clinical Description	A phase 1b/2 study of FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer.
Experiment 3 Reporting the Activity Date of This ADC				[3]
*Related Clinical Trial*
NCT Number	NCT03650491	Clinical Status	Phase 1
Clinical Description	A phase 1 study of FOR46 administered every 21 days in patients with relapsed or refractory multiple myeloma (RRMM).

References

Ref 1	Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 3001-3001.
Ref 2	A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer, NCT05011188
Ref 3	A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM), NCT03650491